Anthera Pharmaceuticals Inc. (Nasdaq: ANTH) reported positive trends from a Week 48 analysis of a Phase 2 BRIGHT-SC proof of concept study lifting the stock price 56 cents to close at $2.03.
Anthera Pharmaceuticals reports positive trends
December 07, 2016 at 16:26 PM EST
